Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 5

Apolipoprotein E ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity

Authors Kotze M, Luckhoff H, Brand T, Pretorius J, J van Rensburg S

Received 1 April 2014

Accepted for publication 8 May 2014

Published 12 January 2015 Volume 2015:5 Pages 9—18

DOI https://doi.org/10.2147/DNND.S41721

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Video abstract presented by Kotze MJ.

Views: 906

MJ Kotze,1 HK Lückhoff,1 T Brand,1 J Pretorius,1 SJ van Rensburg2

1Division of Anatomical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa; 2Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University and the National Health Laboratory Service, Tygerberg Hospital, Tygerberg, South Africa

Abstract: Alzheimer’s disease (AD) displays a high degree of heterogeneity in terms of its etiology, presentation, prognosis, and treatment response. This can partly be explained by high-penetrance mutations in the amyloid precursor protein, presenilin 1 and presenilin 2 genes causing amyloid beta aggregation, which is a major pathogenic mechanism in the development of early-onset AD in a small subgroup of patients. Late-onset AD is considered a polygenic disorder in which cumulative risk resulting from interaction with modifiable environmental risk factors may be responsible for the majority of cases. The ε-4 allele of the apolipoprotein E (APOE) gene has emerged as the most significant genetic risk factor for late-onset AD, influencing nearly every pathogenic domain affected in AD. It is a major risk factor for cerebral amyloid angiopathy, recognized as a common pathological finding in an AD subtype associated with white matter dysfunction. The APOE ε-4 allele is also a known risk factor for ischemic stroke, which can result in vascular dementia or contribute to subcortical vascular dysfunction. In this review, we evaluate the clinical relevance of APOE genotyping in relation to cholesterol metabolism and available evidence on risk reduction strategies applicable to AD.

Keywords: Alzheimer’s disease, heterogeneity, APOE, cholesterol, polymorphism, pharmacogenetics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]